This systematic review and meta-analysis provide robust evidence that GLP-1 RAs are highly effective for producing clinically significant weight loss and improving multiple cardiometabolic outcomes in individuals with overweight or obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.